Centogene appoints patrice p. denÈfle as chief scientific officer to lead its data-driven approach to reinvent rare disease drug discovery and development

Cambridge, mass. and rostock, germany and berlin, july 27, 2021 (globe newswire) -- centogene n.v. (nasdaq: cntg), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the appointment of dr. patrice p. denÈfle as chief scientific officer (cso). dr. denÈfle will join centogene on august 16, 2021, succeeding phil lambert, who has decided to leave the company.
CNTG Ratings Summary
CNTG Quant Ranking